INTRODUCTION
The risk of cardiovascular disease and heart failure is elevated in diabetes (1) . In the Framingham study, for example, the incidence of heart failure in diabetes was elevated two-fold in diabetic men and three-fold in diabetic women compared with matched non-diabetic participants (24) .
Diabetic cardiomyopathy (DCM) was described in 1972 on the basis of observations in four diabetic patients, who presented with heart failure without evidence of hypertension, coronary artery disease, or congenital heart disease (33). Since this publication, the existence of diabetic cardiomyopathy as a distinct clinical entity has been under debate; however a recent review by Fang et al., summarized evidence that strongly supports the existence of diabetic cardiomyopathy independent of co-morbid conditions (14) . DCM is now held to refer to a disease process that affects the myocardium in diabetic patients, causing a wide range of structural abnormalities including interstitial fibrosis, and eventually leading to left ventricular hypertrophy (LVH), and diastolic or systolic dysfunction or a combination of these. The concept of diabetic cardiomyopathy is based upon the idea that diabetes is the antecedent factor which causes changes at the cellular level, leading to structural abnormalities (19) .
In addition, there is increasing evidence that altered substrate supply and utilization by cardiac myocytes could be key to the tissue injury in the pathogenesis of this disease (14) . The ability to switch from fatty acid -oxidation to carbohydrate oxidation is impaired in diabetes, producing a state known as metabolic inflexibility (42); this is believed to lead to an increased reliance by the heart on fatty acids as its primary fuel supply and to decrease the ability of the heart to adapt to stress.
A third aspect of diabetic cardiomyopathy is the observed increase in reactive oxygen species (ROS) and the effect that this has on the cell (31) . It has been hypothesized that excess ROS cause much of the cellular damage underpinning the downstream complications of this disease (6) .
Until now, the multi-factorial nature of diabetic cardiomyopathy has made it difficult to examine all the concomitant tissue changes that interact to generate the observed pathophysiology.
The advent of microarray technology however, has enabled simultaneous investigation of all changes in gene expression that occur in diabetic cardiomyopathy (18) .
The aim of this study was to develop an improved understanding of the transcriptional changes that occur in the cardiac LV following 16 weeks of uncontrolled diabetes. Using this methodology, we have characterised the attendant molecular changes more completely than has previously been reported. The findings reported here have significance in further defining the molecular pathophysiology of diabetic cardiomyopathy, an increasingly recognised and potentially fatal disease of the heart.
RESEARCH DESIGN AND METHODS
Animal model. Male Wistar rats (220-250 g; University of Auckland) were randomised into 2 groups prior to injection. They were anesthetized (halothane 2-5 %) and then administered 60mg.kg -1 of freshly prepared streptozotocin (STZ, Sigma-Aldrich) via tail-vein injection; controls (normal) received the corresponding volume of saline (0.3-0.5 mL final). Animals were recovered and housed in pairs on fibrecycle bedding (12 hr light:dark cycle, 50-70 % humidity, 19-21°C). Initial
[glucose] blood and bodyweight were measured at the time of injection and 2 days afterwards, and were thereafter monitored weekly. Diabetes was diagnosed as a sustained [glucose] blood > 11mM and insulin was not administered. All procedures and protocols were approval by the University of Auckland Animal Ethics Committee.
Cardiac structure and function. In a parallel study, similarly-treated diabetic and sham rats were prepared and cardiac performance measured using an isolated-perfused working heart model to confirm cardiomyopathy had been established. Animals were anesthetized and heparinized (200 i.u./kg i.v.), and hearts excised and immersed in 4°C Krebs-Henseleit bicarbonate buffer (KHB).
Retrograde (Langendorff) perfusion was established (KHB, 37°C, gassed with O 2 :CO 2 95:5 [v/v]). Working-mode perfusion was then established (pre-load, 10 cmH 2 0; afterload, 55.9 mmHg) with pacing (300 bpm; Digitimer) and intra-chamber LV pressure (SP855; AD Instruments) and cardiac output (Transonic T206) measured. Pressure and flow data were recorded (Powerlab16s, ADI), and ventricular pressure development (+dP LV /dt) and relaxation (-dP LV /dt) were derived. Atrial filling pressure was decreased (5 cmH 2 0) and then increased (seven steps of 2.5 cmH 2 0 to 20 cmH 2 0
[final]), and 1-min averages were extracted. Inter-group differences were contrasted (mixed models/repeated measures; SAS v8.1).
Tissue processing. 16 weeks after diabetes induction, animals were anesthetized (halothane 2-5 %) and given heparin (i.v. 200 i.u./kg; Mayne Pharma Pty Ltd, Aus.). Animals were killed by cervical dislocation and hearts rapidly excised in an RNase free environment. The aortic remnant was tied to a custom-made perfusion apparatus and perfused with 40-60 mL phosphate buffer solution (PBS: NaCl, 137 mM; KCl, 2.7 mM; Na 2 HPO 4 , 4.29 mM; KH 2 PO 4 , 1.46 mM) at 4 o C, flow rate 15 mL/min (GENIE 220 pump) until no blood was evident in the eluent. The left ventricle (LV) was then dissected from the rest of the heart and placed in RNAlater (Qiagen Inc., CA, USA).
Microarrays.
RNA from the LV of 14 animals was obtained using either the Qiagen MIDI RNeasy RNA extraction kit or the Ambion Mini RNAqueous RNA extraction kit, as per protocols. RNA was quantitated using a NanoDrop ® ND-1000 (NanoDrop Technologies, DE) and the quality of RNA determined (Bioanalyzer; Agilent Technologies Inc., CA). An RNA integrity number (RIN) of 8.5 was considered adequate for analysis.
Five µg from each RNA preparation was used to make a hybridisation mixture containing 15 µg biotinylated cRNA (Affymetrix protocol) and adjusted for possible residual RNA carryover.
Complementary RNA was overnight-hybridised to a microarray chip (Affymetrix Rat GeneChip 230 2.0) before scanning (Affymetrix Scanner 3000) and processing (GCOS, Affymetrix). The mean cardiac/body mass ratio was increased by 23 % in diabetic compared to control animals, indicating an increase in the relative size of the diabetic heart despite there being significantly lower absolute cardiac (Fig. 1A ) and body weights (data not shown). Diabetic animals gained weight more slowly than normal controls (Fig. 1B) .
In order to identify that our model showed signs of established DCM, we performed an exvivo perfused heart study. Isolated hearts from diabetic animals had impaired systolic and diastolic function when compared to controls (Fig. 1C, 1D ), which was associated with deterioration in cardiac performance and is consistent with previous reports (7, 8, 11, 12) .
Gene expression. Analyses of changes in gene expression after 16 weeks' diabetes were performed in LV RNA that was isolated from 7 random animals in each of the STZ-diabetic and normal groups and then hybridized to 14 Affymetrix arrays. Statistical analysis of the expression data produced a list of genes whose expression was changed significantly in diabetes (Tables 3, 4) . For each gene, the P-value (P) was used to determine significance rather than fold-change, to include a much larger proportion of candidate gene changes. Using this criterion, 1,614 significant changes were determined (each P < 0.05) from a total of 31,100 spots on the array.
Changes in expression of genes that encode cardiac structural proteins. As noted above, diabetic hearts had larger relative masses (Fig. 1A) Disturbances in expression of genes whose products regulate energy metabolism. The percentage of gene changes in specific cellular compartments were analyzed using the Gene Ontology (GO) cellular component classification system (1) (Figure 3 ). The largest proportion of diabetes-modified genes detected was associated with 'membrane' or 'plasma membrane' components. The second was genes associated with the mitochondria, a feature that is noteworthy due to the mitochondrion's association with energy metabolism (38, 41, 42, 44). Our microarray results (discussed below) provide a unique global snapshot of the underlying molecular processes that until now have frequently been considered in various studies of isolated pathways. We now highlight a number of interesting points that relate to the changes in cardiac energy metabolism that occur in severe diabetes.
Glucose Metabolism. We found decreases in both GLUT1 and 4 mRNAs as well as changes in key metabolic regulatory enzymes such as pyruvate dehydrogenase phosphatase (PDP2) and pyruvate dehydrogenase kinase (PDK4), both of which play roles in the transport of pyruvate into the mitochondria (all genes involved in glucose metabolism found to be altered in this study are presented in Table 3 ). In accordance with previous reports (12), GLUT4 and GLUT1 expression were both decreased, by 25 % and 50 % respectively, consistent with a marked diminution in myocardial glucose uptake capacity. By contrast, PDK4 increased 690 % in diabetic compared to normal individuals (confirmed by RTqPCR), whereas PDP2 was decreased 59 % in diabetic tissue (Table 2 ).
In mitochondria, the kinase (PDK4) and phosphatase (PDP2) are simultaneously active and their relative activities determine the proportion of inactive/active pyruvate dehydrogenase (PDH) complex (25) . It has been hypothesized that an increase in the amount of PDK4 protein leads to greater phosphorylation and lower activity of the PDH complex. This is said to suppress glucose and lactate oxidation and favor fatty acid oxidation (47). Such changes could be further enhanced by the increase in PDP2 expression seen here and by Huang et al., who reported that STZ-induced diabetes (48-hours' duration) decreased both protein and mRNA levels of PDP2 in the heart (20) .
Together these findings emphasize that concurrent upregulation of PDK expression and downregulation of PDP expression likely contributes to hyper-phosphorylation of PDH in diabetes (20) .
Inhibition of this complex can exacerbate the diabetic state by inappropriately sparing glucose and gluconeogenic substrates from complete oxidation despite abundant [glucose] blood (47).
Fatty acid metabolism.
In diabetes, the heart is exposed to an environment that is both hyperglycemic and hyperlipidemic (42). In contrast to glucose metabolism-related genes, however, we found that those involved in fatty acid uptake and oxidation were generally up-regulated (Table 4 ). Here, CD36/fatty acid translocase (CD36/FAT) was increased 41 % in the diabetic compared to the normal (Table 4) , consistent with the hypothesis that there is increased overall fatty acid uptake in diabetic myocardium. CD36/FAT has been identified as one of three fatty acid transport proteins that increased fatty acid uptake when over-expressed in cell lines (30) and it is thought to be the primary fatty acid transporter in cardiac and skeletal muscle (30) . This result and the disproportionate increase in lipid metabolism genes has been recently confirmed in LV tissue after only 2 weeks of diabetes (27) indicating that this is an early and sustained change. Taetgtmeyer In our study we report for the first time the up-regulation of angiopoietin-like protein 4
(Angptl4) in a diabetic heart (25-fold increase relative to normal tissue). Angptl4, is also known as PPAR angiopoietin-related fasting-induced adipose factor or hepatic fibrinogen/angiopoietinrelated protein (16) and has been shown to be a potent inhibitor of lipoprotein lipase (LPL) activity, leading to increased serum triglyceride levels (49). The highest expression of Angptl4 is found in white adipose tissue, however there is significant expression previously reported in normal liver, heart and skeletal muscle (26) . As a transcriptional target of PPAR , Angptl4 has been hypothesized to play a role in the modulation of adipogenesis, insulin sensitivity or energy metabolism and is elevated in genetically obese mice (16) .
A recent study published by Yu et al., looking at heart specific over expression of Angptl-4 in mice, found that the presence of an Angptl-4 transgene in the heart caused an 80 % reduction in cardiac LPL activity and a greater than 2 fold increase in fasted plasma triglyceride levels (50). Our current work supports this finding with a 25-fold up-regulation of Angptl-4 and a 2.8-fold increase in serum triglycerides (see Table 1 ). Further studies by Yu et al., found that over expression of Angptl-4 led to altered substrate oxidation and impaired cardiac function similar to that seen in cardiomyopathy. They were able to show a 60 % reduction in triglycerides (intralipid) utilization in the Angptl-4 transgenic mouse during isolated perfused heart studies (50).
The heart obtains FA for use as an energy source through 3 different pathways: circulating FFA's bound to albumin, circulating chylomicrons and VLDL which require LPL before utilization and hydrolysis of triglycerides present in the cardiomyocyte (50). Our current study is consistent with the view that the heart is not able to use the LPL pathway to obtain FFA for energy use and it therefore this likely comes from one of the other two pathways.
The gene-products that channel fatty acids into the mitochondria are: carnitine palmitoyl transferase 1 (CPT1 ), which increased 116 %; carnitinie:acylcarnitine translocase (solute carrier family 25, member 20), which increased 30 %; and carnitine palmitoyl transferase 2, which increased 40 % in diabetic animals (Table 4) . Fatty acid oxidation is limited by the transport of fatty acid residues into the mitochondria through CPT1 (12). The two isoforms of CPT1 (CPT1 and CPT1 ) are both expressed in the rat heart. Cook et al., (10) reported that STZ-induced diabetes resulted in increased CPT1 but that CPT1 levels remained the same. CPT1 is predominantly expressed in the fetal heart and gradually reduces in expression as the rat develops. This increase in CPT1 observed in the current study indicates the heart may be increasingly reliant on fatty acids as a fuel source and provides evidence for the accumulation of acylcarnitine and intermediates in the heart during diabetes (40).
CPT1 is regulated mainly through inhibition by malonyl-CoA (34). Increased expression of malonyl CoA-decarboxylase (MCD), a negative regulator of malonyl-CoA production, could decrease the malonyl-CoA available to inhibit Cpt1. We found a significant increase (50 %) in expression of MCD in the diabetic (Table 4 ) and this result was confirmed by RTqPCR (Table 2) .
These results indicate that there are at least two factors contributing to the reported increase (40) in transport of fatty acylcarnitine into the mitochondrion. One is decreased inhibition of CPT by malonyl-CoA (both isoforms) and the other is increased expression of the transporting proteins CPT1 and , both of which potentially lead to excess fatty acids within the mitochondrion.
Once fatty acids have been transported into the mitochondrion, they are converted to acetylCoA through -oxidation and the tri-functional -oxidation complex (TOC) (48). Here, we found that three of the four genes whose products comprise the TOC: enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase and acyl-Coenzyme A dehydrogenase very long chain, were increased in the diabetic state compared to normal. A proteomic analysis of changes in mitochondrial proteins with diabetes reported a similar array of -oxidation protein changes (45).
Therein, a number of proteins studied from the tricarboxcylic acid (TCA) cycle were unchanged in diabetes (45); that finding is consistent with our results and provides further evidence that, although the heart is taking up and processing more fatty acids, a similar increase is not observed in the TCA cycle, which could explain the increase in unused acyl-CoA. Furthermore, this result is also consistent with the hypothesis of Taegtmeyer et al., (42) by which fatty acid uptake exceeds the rate of -oxidation leading to myocellular lipid accumulation and lipotoxicity. For an overview of the processes described in this section and in glucose metabolism, see Figure 3 .
In summary, much evidence supports the idea that increased fatty acid oxidation and accumulation in the heart substantively contribute to the damage seen in diabetes. Our results are also consistent with the hypothesis (42) that, when fatty acid availability exceeds its oxidation rate, intramyocardial lipid accumulation occurs that could lead to lipotoxicity, which in turn might induce ROS accumulation, iNOS induction and apoptosis.
ROS generation -a hypothesis for changes in gene expression (6) Linkages between PKC activation, AGE formation, increased flux through the polyol pathway, decreased GSH, and ROS formation have been reported by Nishikawa et al., (31) , who suggested that, in cultured endothelial cells, the TCA cycle might be the source of increased ROS-generating substrate induced by hyperglycemia (31) . As a result of the observed changes in genes involved in fuel metabolism we decided to assess expression of genes implicated in diabetic complications resulting from increased ROS, focusing specifically on the pathways outlined above (6) . Glutathione (GSH) participates in the cellular defence against oxidative stress by reducing disulfide bonds in proteins and other intracellular molecules or by scavenging free radicals and reactive oxygen intermediates (46). Here, we found expression changes in several genes involved in GSH metabolism, such as members of the glutathione S-transferase family. This family of enzymes utilize glutathione in reactions contributing to the transformation and detoxification of a wide range of compounds, including carcinogens, therapeutic drugs, and products of oxidative stress (39). Expression of nine GSH Stransferase family members, including one specific to mitochondria, was significantly altered. Of these, six were increased in diabetes, which could explain decreased GSH availability for cellular defence and implicate this pathway as one which may contribute to ROS increases.
Another pathway previously implicated is the protein kinase C (PKC) pathway. Inoguchi et al., (22) reported increased membranous PKC activity and total DAG in the diabetic rat heart. In this study we found that PKC-was increased 30 %. Others have suggested, based on immunohistochemical studies in aorta and heart that PKC-and PKC-appear to be preferentially activated in diabetic rats (28) . Increased PKC activity in diabetic cardiovascular tissues may lead to alterations in expression of several growth factors, cytokines and vasoactive molecules, including endothelin-1 (ET-1). The endothelin family interacts with three receptor populations: ET A , ET B and ET C . Endothelin and its receptor mRNAs were reportedly increased in retinas from diabetic rats (8).
In our microarray study, the endothelin receptors A and B were both increased 59 % and 92 % respectively in diabetes, which implies that there is a pathway based change occurring in this instance.
Of note, AGE formation and the hexosamine pathways were not found to have gene changes associated with them. This may be a result of non-gene related changes occurring (particularly in the case of AGE formation) or a dilution effect occurring due to the nature of the cell types within the myocardium. The myocardium is made up of cardiomyocytes, fibroblasts and endothelial cells.
Much of the publications cited in our discussion were derived from cultured endothelial cells (6, 31) ; it may be that specific cell expression analysis is required in order to fully determine the contributions of each cell type to the overall damage seen in DCM
The linking factor between ROS overproduction and the activation of the four pathways outlined above has been proposed to be activation of the nuclear DNA-repair enzyme poly (ADPribose) polymerase (PARP) (13) . Here, expression of PARP (TCDD-inducible PARP) was increased 28 % in diabetic compared to control heart. Normally, PARP resides in the nucleus in an inactive form. Brownlee et al., reported that increased intracellular glucose generates increased mitochondrial ROS, thereby inducing DNA-strand breaks and activating PARP. Once activated, PARP catalyzes polymerization of ADP-ribose, which reportedly accumulates on GAPDH and other nuclear proteins (6) . PARP modification of GAPDH reportedly decreases its activity, leading to activation of the polyol pathway, increased intracellular AGE formation, and activation of PKC, NF B and hexosamine pathway flux (6).
Relationship of fatty acid oxidation to ROS generation and mitochondrial function. One prominent hypothesis, by which excessive ROS production might lead to diabetic complications, has in the main been derived from studies in endothelial cells (6) . These have high, fixed glucoseuptake capacity and so are vulnerable to large glucose influxes driven by mass action in hyperglycemia (5). By contrast, glucose transport is decreased and fatty acid transport increased in other cardiac cell-types, despite high circulating glucose. However, oxidation of fatty acids and acetyl-CoA generates the same electron donors as glucose oxidation. Thus, increased fatty acid oxidation can drive excess mitochondrial ROS production via the same down-stream mechanism as glucose (6). St-Pierre et al., (37) reported that rat skeletal muscle and cardiac mitochondria produced measurable rates of H 2 O 2 (ROS precursor) when respiring on palmitoyl carnitine but not when utilising pyruvate or succinate (37), which is also consistent with this mechanism.
Partial evidence for increased ROS generation by fatty acid oxidation in this study comes from an observation that UCP-3 mRNA levels were increased 150 % in diabetic myocardial tissue (Table 4) . UCP-3 mRNA expression is increased when fatty acids are high (37) as well as in skeletal muscle of db/db mice (9). UCP3's role is currently debated, but a recent review identified four distinct models for its possible function (4) . One prominent hypothesis is that UCP family members attenuate mitochondrial free radical production, thereby protecting tissues against oxidative damage. Mitochondrial ROS production is sensitive to the proton-motive force established across the inner membrane by electron transport, so the mild uncoupling caused by activation of UCP3 might lower this force slightly, thereby attenuating ROS production and protecting against ROS-mediated cellular damage (4). An increase in UCP3 mRNA is consistent with the hypothesis of a diabetes-evoked increase in fatty acids leading to increased ROS production and a requirement for its protective up-regulation. Further study is required to determine whether this effect occurs through attenuation of free radical production or export of fatty acids and their peroxides from the mitochondria (see (4)).
Conclusion.
We have shown here that genes corresponding to proteins expressed in mitochondria account for a disproportionate number of those whose expression was significantly modified in DCM. We interpret these findings as being consistent with the hypothesis that mitochondria act as key targets of the pathogenic processes that cause diabetic heart disease. Furthermore, our transcriptomic analysis is also consistent with the hypothesis that diabetes induces global perturbations in the expression of genes regulating fatty acid metabolism, whose dysfunction is likely to play a key role in the promotion of oxidative stress, thereby contributing to diabetic myocardial disease. In particular, our study points to impaired regulation of mitochondrialoxidation as central in the mechanisms contributing to DCM pathogenesis. We note that these 
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Cytochrome b5 (CytB5) is a marker for mtDNA and has been used previously to quantitate mtDNA copy number (51). *Transcription factor A, mitochondrial (Tfam) is a negative control, since it was not significantly changed on microarrays. Analysis was by Ct (see Methods). Fold Change: The fold change in the diabetic compared to control animals. >1 is increased expression in the diabetic and <1 is decreased expression in the diabetic compared to control. * at least P < 1.0E-05 Fold Change: The fold change in the diabetic compared to control animals. >1 is increased expression and <1 is decreased expression in the diabetic compared to control. * at least P < 1.0E-05 
